Apart from Wockhardt, only Biocon manufactures insulin analog indigenously.
Industry leaders have urged the government to carry forward the reforms process.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Another cap for imported insulin; domestic manufacturers cry foul.
Over two dozen companies have announced bonus issue so far in 2017
ICICI Bank CEO and MD Chanda Kochchar, Biocon founder Kiran Mazumdar-Shaw and film producer Ekta Kapoor are among the nine Indian women named in Forbes magazine's inaugural 'Asia Power Businesswomen list'.
Other corporate leaders, including Biocon chief Kiran Mazumdar Shaw, UB Group Chairman Vijay Mallya and Mahindra Group vice-chairman Anand Mahindra, have also expressed concerns over the current state of economy in the country.
Taking a break from their hectic schedule and boardroom meetings, nine CEOs would display their singing prowess at a charity dinner event in Bengaluru to raise funds for children on July 16.
The list acknowledges the 'inroads women are making in the business world'.
In this second part - of 'Glass-ceiling in India' - we bring you India's successful entrepreneurs. These women are stereotype-busters in their own right.
Three Indians PepsiCo chief Indra Nooyi, ICICI Bank's CEO Chanda Kocchar and Kiran Mazumdar Shaw of Biocon -- have been listed in 'The World's 100 Most Powerful Women' list by Forbes magazine.
The story of Kiran Mazumdar-Shaw is one of grit, self confidence and courage. If today she is one of the most successful entrepreneurs in the world, it is because of her determination.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
In this part, we highlight some of Karnataka's leading entrepreneurs. They are the ones who played a key role in defining its present cosmopolitan status, giving Karnataka a resonance in history and in international relations.
In this part, we highlight some of Karnataka's leading entrepreneurs. They are the ones who played a key role in defining its present cosmopolitan status, giving Karnataka a resonance in history and in international relations.
"My view on taxation levels in India is that it is at a reasonable level and I think what is more important is how the government uses taxpayers' money," said Kiran Mazumdar-Shaw, the Chairman and Managing Director of Biocon, India's largest biotech company by revenue, said.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Founders of the Garden City's technology companies are learning the art of patience when it comes to meeting CSR objectives.
The rupee's appreciation of 6.4 per cent against the dollar and 12 per cent against the euro is likely to hurt the first-quarter performance of the pharmaceutical sector, indicate a results' preview by broking houses.
India's biotechnology industry is pushing the government for fiscal incentives, import duty exemption and correction of policy that gives MNCs higher drug prices than "desi" producers, ahead of the Union budget.
In a recent awards event, industrialist Rahul Bajaj said that India Inc was afraid of criticising the Narendra Modi government, The comment drew flak from Finance Minister Nirmala Sitharam who said spreading one's own impression "can hurt national interest".
Bt brinjal is a genetically-modified vegetable which is infused with Cry1Ac gene from a bacterium Bacillus thuringiensis to make the plant resistant to the fruit and shoot borers and certain pests.
India was a very important strategic partner of the US, she said.
Indian drug companies, which have introduced copies of biotechnology drugs in the country, are bullish over the marketing prospects of 'biogenerics' after patents expire in developed markets. Experts say Indian companies may not repeat the success they achieved in selling generic medicines in biogenerics. The cost of clinical trials and the absence of substitutability will ensure that only those with deep pockets to launch such products globally will succeed, they feel.
The top 200 companies were picked from over 12,000 publicly-listed firms with sales of less than $1 billion in the Asia-Pacific region.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Clinical trials, agri-biotech and bio-fuels are becoming opportunities. There are a lot of growth drivers and trigger points which, she said, will deliver in the next five years.
Bengaluru's celebs wish the newly-weds.
Others in the top 10 include Uday Kotak at the 6th place with a wealth of Rs 94,100 crore, Cyrus S Poonawalla at 7th position with Rs 88,800 crore assets, Cyrus Pallonji Mistry at 8th spot with a wealth of Rs 76,800 crore, Shapoor Pallonji at 9th position with a net worth of Rs 76,800 crore and Dilip Shanghvi at 10th slot with Rs 71,500-crore wealth.
Sitharaman, who is not known to reply to comments made on her Twitter handle, instantly choose to respond to drug-maker Biocon chairman Kiran Mazumdar-Shaw's criticism of lack of fiscal measures to support growth.
The Clinical Research sector is emerging as an attractive option for science graduates, doctors, management/ IT professionals, alike.
New drug discovery and contract research have taken a back seat as global drug majors have slowed down their research and development offshoring to India.
In an interview with Nandita Datta she talks about biotechnology becoming the new buzzword and what it takes to build a successful career.
As Covid-19 cases surge in India, companies have realised it's a tightrope walk between maintaining production and ensuring employee safety.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Bharti Airtel Chairman Sunil Bharti Mittal said India has lost one of the finest political leaders and a legal luminary.
As many as six women, including O P Jindal group chairperson Savitri Jindal and Biocon's Kiran Mazumdar Shaw, have made it to the Forbes' list of 100 richest Indians this year.
The only category of pharmaceuticals that showed a negative growth in exports this time was herbal products, exports of which stood at $299 million as compared to $ 312 million in the previous year.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries
The less-than-anticipated results of a few big-ticket acquisitions made in the previous year earlier also acted as a dampener. Piramal Healthcare, Biocon and other drug makers spent about Rs 1,800 crore (Rs 18 billion) in 2008 for acquiring assets abroad, compared to more than Rs 5,500 crore (Rs 55 billion) spent in 2007 in 14 such major deals, according to Business Standard data.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances